Company intelligence / Profile preview
Prime Medicine, Inc.
Cambridge, Massachusetts, United Statesprimemedicine.com ↗
- Ownership
- Public · PRME
- Development stage
- Phase 1
01
Overview
Prime Medicine is advancing multiple programs in pre-clinical stages, with a focus on hematology, immunology & oncology, liver, and lung diseases. The company recently unveiled a program for Alpha-1 Antitrypsin Deficiency (AATD) in March 2025.
- Therapeutic areas
- ImmunologyRare DiseasesPulmonology
- Modalities
- Gene editingPrime Editing
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Bristol Myers Squibb (September 2024, for ex vivo T-cell Prime Editor products)Cystic Fibrosis Foundation (January 2024, up to $15 million to support development of Prime Editors for Cystic Fibrosis)
04
Financials
- Market cap
- $807.1M
- Total revenue
- $4.6M
- Enterprise value
- $824.5M
Beyond the preview
Go deeper on Prime Medicine, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prime Medicine, Inc..